Drugs / AN8025
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07639047 | Nov 2025 → Jul 2027 expected | — | Adlai Nortye Biopharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AN8025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07639047 ↗ |
| Modality | Protein / enzyme biologic | “AN8025 is a multifunctional antibody fusion protein” NCT07639047 ↗ |
| Route | Intravenous | “intravenously administered over the period of 60 mins.” NCT07639047 ↗ |